Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

$Inhibikase Therapeutics (IKT.US)$ $Inhibikase Therapeutics ...

JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.


The Company is completing 13-week pivotal toxicology studies to be submitted to the FDA for review in August.

CEO excised options

$Inhibikase Therapeutics (IKT.US)$ $Inhibikase Therapeutics (IKT.US)$ $Inhibikase Therapeutics (IKT.US)$  JonesTrading analyst Soumit Roy initiates coverage on ...
$Inhibikase Therapeutics (IKT.US)$ $Inhibikase Therapeutics (IKT.US)$ $Inhibikase Therapeutics (IKT.US)$  JonesTrading analyst Soumit Roy initiates coverage on ...
kepos capital bought 700,000 shares, bull soon🐂🐂

Ex–Goldman Sachs
Quant Mark Carhart Is
Launching A New Firm

By launching Kepos Capital, Carhart aims to prove that quantitative global macro is stronger than ever.
$Goldman Sachs (GS.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
7
+0
1
Translate
Report
255K Views
Comment
Sign in to post a comment
  • supastarcwet23 : we keep thinking black rock is good under your stock..those are the same people shorting under every stock and I've notice their name comes up with a lot of manipulation stocks..crazy man

152Followers
40Following
490Visitors
Follow